Loading
A phase 1/2 trial of Ruxolitinib and Fedratinib in myeloproliferative neoplasms, run by Bristol-Myers Squibb, active and no longer recruiting.
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) is a phase 1/2 interventional study registered as NCT04817007 by Bristol-Myers Squibb, with 216 participants enrolled, started 2021-03-22 and due to reach its primary completion in 2028-08-31. Interventions recorded: BMS-986158, Ruxolitinib and Fedratinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ruxolitinib, Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors and the tag pipeline.
Shares Ruxolitinib, Primary myelofibrosis and the tag pipeline.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Ruxolitinib, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors and the tag pipeline.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb, Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/